Market research
UXI4.F Cyclacel Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 183K
- P/E ratio
- Not available
- Analyst target
- 20.25
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23254L6039
- Market cap
- 183K
- P/E ratio
- Not available
- Analyst target
- 20.25
- Dividend yield
- Not available
- Beta
- 0.85
About
About Cyclacel Pharmaceuticals, Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the UXI4.F discussion.
5 years, 5 months ago
Cyclacel Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 71.0.
Cyclacel Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 21.6% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-1M since the same quarter in the previous year.
Based on the above factors, Cyclacel Pharmaceuticals, Inc gets an overall score of 1/5.